Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures
Summary
The aim of this clinical trail is to evaluate the efficacy of a Carbogen inhalation in patients with febrile seizures compared to a placebo-inhalation. Further aims are the evaluation of the safety of the Carbogen inhalation via a low-pressure can with a breathing mask in a home-setting, the manageability of the Carbogen inhalation via a low pressure can with a breathing mask in a home-setting or on the way (mobility), the quality of life of the parents and children using the low pressure can with a breathing mask in a home-setting or on the way (mobility) and the contentment and anxiety of the parents.
Timeline
- Start
- 2012-08
- Primary completion
- 2015-06
- Completion
- 2015-06
Outcome
Missed primary endpoint
Stopped: “results of interim analysis (not safety relevant)”
paper The febrile seizure was terminated in 5/15 episodes on carbogen and in 8/11 episodes on oxygen (Fischer's exact test; p = 0.11). PMID 41433250 ↗
paper In conclusion, carbogen did not interrupt acute febrile seizures more often than placebo. PMID 41433250 ↗
Publications
- Background Ohlraun S, Wollersheim T, Weiss C, Martus P, Weber-Carstens S, Schmitz D, Schuelke M. CARbon DIoxide for the treatment of Febrile seizures: rationale, feasibility, and design of the CARDIF-study. J Transl Med. 2013 Jun 27;11:157. doi: 10.1186/1479-5876-11-157.
- Weiss C, Hucko A, Muller-Ohlraun S, Marschenz S, Martus P, Schmitz D, Schuelke M. The use of carbogen for interruption of febrile seizures - the randomized controlled CARDIF trial. PLoS One. 2025 Dec 23;20(12):e0324422. doi: 10.1371/journal.pone.0324422. eCollection 2025.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carbogen | Other / unclassified | 5 % | Inhaled |
Indications
No indication recorded.